Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated recombinant human endostatin + docetaxel
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A combination formulation of **pegylated recombinant human endostatin** (commonly known as PEG-Endostar or M2ES)—a PEGylated, recombinant form of the endogenous angiogenesis inhibitor endostatin—and **docetaxel**, a microtubule-stabilizing chemotherapy agent. PEGylation increases endostatin's circulating half-life and stability, enhancing antiangiogenic activity by inhibiting endothelial cell proliferation and tumor angiogenesis[1][2][3]. Docetaxel exerts cytotoxic effects through inhibition of cell division in proliferating tumor cells. The combination is being studied for enhanced anti-tumor effects in solid tumors due to complementary mechanisms: endostatin inhibits tumor blood vessel formation, while docetaxel directly kills dividing tumor cells. Primary indications under investigation include non-small cell lung cancer (NSCLC) and other advanced/metastatic solid tumors[6].
- Brand names
- PEG-Endostar + docetaxelPEG-Endostar injection + docetaxel
- Other names
- PEGylated recombinant human endostatin + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on pegylated recombinant human endostatin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated recombinant human endostatin + docetaxel.